42,403 research outputs found

    Advances in Repurposing and Recycling of Post-Vehicle-Application Lithium-Ion Batteries

    Get PDF
    Increased electrification of vehicles has increased the use of lithium-ion batteries for energy storage, and raised the issue of what to do with post-vehicle-application batteries. Three possibilities have been identified: 1) remanufacturing for intended reuse in vehicles; 2) repurposing for non-vehicle, stationary storage applications; and 3) recycling, extracting the precious metals, chemicals and other byproducts. Advances in repurposing and recycling are presented, along with a mathematical model that forecasts the manufacturing capacity needed for remanufacturing, repurposing, and recycling. Results obtained by simulating the model show that up to a 25% reduction in the need for new batteries can be achieved through remanufacturing, that the sum of repurposing and remanufacturing capacity is approximately constant across various scenarios encouraging the sharing of resources, and that the need for recycling capacity will be significant by 2030. A repurposing demonstration shows the use of post-vehicle-application batteries to support a semi-portable recycling platform. Energy is collected from solar panels, and dispensed to electrical devices as required. Recycling may be complicated: lithium-ion batteries produced by different manufacturers contain different active materials, particularly for the cathodes. In all cases, however, the collecting foils used in the anodes are copper, and in the cathodes are aluminum. A common recycling process using relatively low acid concentrations, low temperatures, and short time periods was developed and demonstrated

    Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.

    Get PDF
    Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, and reduced cost, time and issues related to safety than the conventional drug discovery process. Several drugs have already been successfully repurposed for other clinical conditions including drug resistant tuberculosis (DR-TB). Though TB can be cured completely with the use of currently available anti-tubercular drugs, emergence of drug resistant strains of Mycobacterium tuberculosis and the huge death toll globally, together necessitate urgently newer and effective drugs for TB. Therefore, we performed virtual screening of 1554 FDA approved drugs against murE, which is essential for peptidoglycan biosynthesis of M. tuberculosis. We used Glide and AutoDock Vina for virtual screening and applied rigid docking algorithm followed by induced fit docking algorithm in order to enhance the quality of the docking prediction and to prioritize drugs for repurposing. We found 17 drugs binding strongly with murE and three of them, namely, lymecycline, acarbose and desmopressin were consistently present within top 10 ranks by both Glide and AutoDock Vina in the induced fit docking algorithm, which strongly indicates that these three drugs are potential candidates for further studies towards repurposing for TB

    Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

    Get PDF
    BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant prostate cancer by enhancing the efficacy of docetaxel. METHODS: We performed a drug-repurposing screen by using murine-derived prostate cancer cell lines driven by clinically relevant genotypes. Cells were treated with docetaxel alone, or in combination with drugs (n = 857) from repurposing libraries, with cytotoxicity quantified using High Content Imaging Analysis. RESULTS: Mebendazole (an anthelmintic drug that inhibits microtubule assembly) was selected as the lead drug and shown to potently synergise docetaxel-mediated cell killing in vitro and in vivo. Dual targeting of the microtubule structure was associated with increased G2/M mitotic block and enhanced cell death. Strikingly, following combined docetaxel and mebendazole treatment, no cells divided correctly, forming multipolar spindles that resulted in aneuploid daughter cells. Liposomes entrapping docetaxel and mebendazole suppressed in vivo prostate tumour growth and extended progression-free survival. CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis and reduced tumour growth. Our data support a new concept of combined mebendazole/docetaxel treatment that warrants further clinical evaluation

    Repurposing learning objects: a sustainable alternative?

    Get PDF
    Recent experience shows that reusable learning objects, like the computer assisted learning programmes of the early 1990s, have so far failed to achieve expected levels of integration into educational practice. This is despite technical interoperability, cataloguing systems, high quality standards, targeted dissemination and professional development initiatives. Analysis of this problem suggests that conceptualization of the problem may be limiting the scope of solutions. This paper proposes a sustainable and participative approach to reuse that involves repurposing learning objects for different discipline areas. For some time now there has been a growing awareness that even the most accessible resources have failed to be widely adopted by the educational community and as a result have also failed to fulfil their considerable educational potential. (Campbell, 2003, p. 35

    Universal Broadband: Targeting Investments to Deliver Broadband Services to All Americans

    Get PDF
    Suggests ways to implement Knight's 2009 recommendation for universal broadband access, including repurposing and distributing existing funds via a transparent, market-based approach and supporting adoption by low-income and other non-adopter communities
    • 

    corecore